Scholarlink

Objective <p>To explore the therapeutic mechanism of moxibustion in Crohn disease (CD)-associated intestinal fibrosis by observing its effects on the angiotensin-converting enzyme (ACE)/angiotensin II (Ang II)/angiotensin II type 1 receptor (AT1R) axis in CD mouse models.</p> Methods <p>Six randomly selected male C57BL/6 mice were assigned to a normal group, while the remaining mice were administered 0.1 mL of 2,4,6-trinitrobenzene sulfonic acid via enema to establish a CD intestinal fibrosis model. After successful modeling, the mice were randomly divided into a model group, a moxibustion group, and a Western medication group, with 6 rats in each group. The normal group and the model group only received grabbing without intervention. In the moxibustion group, mild moxibustion was applied to Qihai (CV6) and bilateral Tianshu (ST25) once a day for 10 min each time over 7 consecutive days. The Western medication group was administered mesalazine suspension via oral gavage once a day for 7 consecutive days. At the end of the intervention, the general condition, disease activity index (DAI) score, and gross colon score of mice in each group were evaluated. Hematoxylin-eosin staining was used to observe and score the histological changes in the colon tissue in each group. Masson staining was used to observe colonic fibrosis and the ratio of collagen-positive areas was analyzed; the expression of Ang II in the colon tissue was detected by the enzyme-linked immunosorbent assay; immunohistochemistry and real-time quantitative reverse transcription polymerase chain reaction were used to detect the protein and mRNA expression of ACE and AT1R in the colon tissue, respectively; Western blotting was used to detect the expression of transforming growth factor (TGF)-β1 and connective tissue growth factor (CTGF) in the colon tissue.</p> Results <p>Compared to the normal group, the DAI score, gross colon score, colonic histological score, collagen-positive area ratio, ACE protein and mRNA, Ang II protein, AT1R protein and mRNA, TGF-β1 protein, and CTGF protein in the colon tissue in the model group increased significantly (<i>P</i>&lt;0.01). In contrast, the above indicators in both the moxibustion group and the Western medication group reduced significantly compared to the model group (<i>P</i>&lt;0.01 or <i>P</i>&lt;0.05). There was no statistical difference in these indicators between the moxibustion group and the Western medication group (<i>P</i>&gt;0.05).</p> Conclusion <p>Moxibustion can alleviate intestinal fibrosis in CD mice, and its therapeutic mechanism may be associated with the regulation of colonic ACE/Ang II/AT1R axis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of moxibustion at Tianshu (ST25) and Qihai (CV6) on ACE/Ang II /AT1R axis in the colon tissue of Crohn disease mice with intestinal fibrosis

  • 期刊论文

  • 发表日期：

    2025年6月21日

查看全文
  • Yang Peng,
  • Qianqian Gao,
  • Qianru Feng,
  • Xiaoji Zhu,
  • Zhe Ma,
  • Huangan Wu,
  • Huirong Liu,
  • Cili Zhou

摘要

Objective

To explore the therapeutic mechanism of moxibustion in Crohn disease (CD)-associated intestinal fibrosis by observing its effects on the angiotensin-converting enzyme (ACE)/angiotensin II (Ang II)/angiotensin II type 1 receptor (AT1R) axis in CD mouse models.

Methods

Six randomly selected male C57BL/6 mice were assigned to a normal group, while the remaining mice were administered 0.1 mL of 2,4,6-trinitrobenzene sulfonic acid via enema to establish a CD intestinal fibrosis model. After successful modeling, the mice were randomly divided into a model group, a moxibustion group, and a Western medication group, with 6 rats in each group. The normal group and the model group only received grabbing without intervention. In the moxibustion group, mild moxibustion was applied to Qihai (CV6) and bilateral Tianshu (ST25) once a day for 10 min each time over 7 consecutive days. The Western medication group was administered mesalazine suspension via oral gavage once a day for 7 consecutive days. At the end of the intervention, the general condition, disease activity index (DAI) score, and gross colon score of mice in each group were evaluated. Hematoxylin-eosin staining was used to observe and score the histological changes in the colon tissue in each group. Masson staining was used to observe colonic fibrosis and the ratio of collagen-positive areas was analyzed; the expression of Ang II in the colon tissue was detected by the enzyme-linked immunosorbent assay; immunohistochemistry and real-time quantitative reverse transcription polymerase chain reaction were used to detect the protein and mRNA expression of ACE and AT1R in the colon tissue, respectively; Western blotting was used to detect the expression of transforming growth factor (TGF)-β1 and connective tissue growth factor (CTGF) in the colon tissue.

Results

Compared to the normal group, the DAI score, gross colon score, colonic histological score, collagen-positive area ratio, ACE protein and mRNA, Ang II protein, AT1R protein and mRNA, TGF-β1 protein, and CTGF protein in the colon tissue in the model group increased significantly (P<0.01). In contrast, the above indicators in both the moxibustion group and the Western medication group reduced significantly compared to the model group (P<0.01 or P<0.05). There was no statistical difference in these indicators between the moxibustion group and the Western medication group (P>0.05).

Conclusion

Moxibustion can alleviate intestinal fibrosis in CD mice, and its therapeutic mechanism may be associated with the regulation of colonic ACE/Ang II/AT1R axis.